Home » Venture Capital » Current Portfolio

Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Status Initial Datesort icon
<a href="/venture-capital/all-companies/affinnova-inc">Affinnova, Inc.</a> Pioneering evolutionary algorithms for marketing content optimization. Private 2000 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Novel diagnostics to improve patient outcomes and contain healthcare costs. Public 2000 View Profile
<a href="/venture-capital/all-companies/seahorse-bioscience-inc">Seahorse Bioscience, Inc.</a> Analytical instruments and consumable labware products for biological research and drug discovery. Private 2001 View Profile
<a href="/venture-capital/all-companies/selventa">Selventa</a> Analyzes molecular patient data, accelerates the development process and clarifies decisions on therapeutics and diagnostics Private 2001 View Profile
<a href="/venture-capital/all-companies/helicos-biosciences-corporation">Helicos BioSciences Corporation</a> Innovative genetic analysis technologies for the development and marketing of molecular diagnostics tests. Public 2003 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing, manufacturing and commercializing novel protein therapeutics for orphan diseases and cancer. Private 2004 View Profile
<a href="/venture-capital/all-companies/black-duck-software-inc">Black Duck Software, Inc.</a> Provides products and services for automating the management, governance and secure use of open source software in multi-source development at enterprise scale. Private 2004 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/ls9-inc">LS9, Inc.</a> Developing patent-pending UltraClean™ fuels and sustainable chemicals made with the power of synthetic biology. Private 2005 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Private 2006 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Developing next-generation medical diagnostic products. Private 2006 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Developing environmentally sustainable, low cost, low carbon biofuels from cellulosic biomass. Private 2006 View Profile
<a href="/venture-capital/all-companies/tetraphase-pharmaceuticals-inc">Tetraphase Pharmaceuticals, Inc.</a> Creating novel antibiotics for serious and life-threatening multi-drug resistant infections. Public 2006 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. Private 2007 View Profile
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Pioneering the production of Liquid Fuel from the Sun™. Private 2007 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Optimizing the interface of diagnostic medicine and the healthcare consumer by simplifying blood sampling and testing. Private 2007 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Developing a new class of highly selective targeted and programmable therapeutics called Accurins™. Private 2007 View Profile
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Pioneering a family of high performance, environmentally responsible polymers and chemical intermediates. Private 2007 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing a novel platform for single molecule analysis of proteins. Private 2007 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Private 2008 View Profile